Stem Cell Treatment for HIV is Available at ASCI
Natural Killer Cells are isolated and grown to multiply their numbers. These Virus Fighting cells are then administered back to the patient to increase the patient's natural immunity.
HIV and Natural Killer Cell Treatment
Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.
pubmed: dendritic cell thera... %23 %b %2017 %08:%Jun %+08:00
Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. AIDS Res Hum Retroviruses. 2017 Jun 21;: Authors: Gay CL, DeBenedette MA, Tcherepanova IY, Gamble A, Lewis WE, Cope AB, Kuruc JD, McGee KS, Kearney MF, Coffin JM, Archin NM, Hicks CB, Eron JJ, Nicolette CA, Margolis DM Abstract AGS-004 consists of matured autologous dendritic cells co-electroporated with in vitro transcribed RNA encoding autologous HIV antigens. In an open-label, single arm sub-study of AGS-004-003, AGS-004 was administered monthly to suppressed participants who started antiretroviral therapy (ART) during acute HIV infection. HIV-1 specific T cell responses were measured by multicolor flow cytometry after 3-4 doses. The frequency of resting CD4(+) T-cell infection (RCI) was measured by quantitative viral outgrowth assay. Participants demonstrating increased immune response postvaccination were eligible for analytic treatment interruption (ATI). AGS-004 induced a positive immune response defined as ≥2-fold increase from baseline in the number of multifunctional HIV-1 specific CD28(+)/CD45RA(-) CD8(+) effector/memory cytoxic T-lymphocytes (CTLs) in all six participants. All participants underwent ATI with rebound viremia at a median of 29 days. Immune correlates between time to viral rebound and the induction of effector CTLs were determined. Baseline RCI was low in most participants (0.043-0.767 IUPM). One participant had a >2-fold decrease (0.179-0.067 infectious units per million [IUPM]) in RCI at week 10. One participant with the lowest RCI had the longest ATI. AGS-004 dendritic cell administration increased multifunctional HIV-specific CD28(+)/CD45RA(-) CD8(+) memory T cell responses in all participants, but did not permit sustained ART interruption. However, greater expansion of CD28(-)/CCR7(-)/CD45RA(-) CD8(+) effector T cell responses correlated with a longer time to viral rebound. AGS-004 may be a useful tool to augment immune responses in the setting of latency reversal and eradication strategies. PMID: 28636433 [PubMed - as supplied by publisher]Read more...